Multiplexed knockout of TRAC, B2M, and PD-1 in CD19-specific CAR-T cells demonstrated enhanced anti-tumor activity and reduced alloreactivity, offering promise for more accessible, universal CAR-T therapies (Stenger et al., 2020; Song et al., 2024). Here, PDCD1 is linked to neoplasm.